XMD8-92

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：XMD8-92	Purity：98% min
CAS NO：1234480-50-2	Solubility：DMSO : 50 mg/mL (105.36 mM)
Molecular Formula：C₂₆H₃₀N₆O₃	Package：Package according to customer requirements
Molecular Weight：474.555	Storage：Store at -20℃

Quality control

Remarks

XMD8-92 is a BMK1 inhibitor and a highly selective inhibitor of ERK5 activity. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. XMD8-92 blocks cellular BMK1 activation and significantly suppresses tumor growth in lung and cervical tumor models and is well tolerated in animals.

Chemical Name:

2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one

Chemical Properties:

Boiling point: 741.8±70.0 °C(Predicted)

density: 1.301

pka: 14.76±0.20(Predicted)

Epigenetic Reader Domain Inhibitors Related Products:

ICG-001; (+)-JQ1; I-BET151; PFI-1; Molibresib; Apabetalone; C646; Curcumin; Bromosporine; Birabresib; UNC1215; GSK6853; CPI-637; BI-9564; PFI-4; MS436; CPI-203; KG-501; Mivebresib ; GSK2801

References

[1]. Yang Q, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.Cancer Cell. 2010 Sep 14;18(3):258-67.

[2]. Yang Q, et al. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res. 2011 Jun 1;17(11):3527-32.

[3]. Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7(349):ra102.